PCOS Blend

Description

PCOS Blend is a scientifically validated blend of myo-inositol (MI) and D-chiro-inositol (DCI) in a 40:1 ratio, as well as other antioxidants. This supplement is a first-line treatment for PCOS that can improve several metabolic abnormalities associated with polycystic ovarian syndrome (PCOS).

This product is designed for females with PCOS and it is an insulin-sensitizing agent that treats ovulation dysfunction related to insulin resistance. It helps re-establish normal menstrual cycles and ovulation and may increase the chance of spontaneous pregnancy.

Ingredient List:

Myo-Inositol: Ubiquitous B complex vitamin that is a second messenger for several hormones. It is the inositol specific to the ovaries.
D-chiro Inositol: Chemical twin but functionally different from myo-inositol that is an insulin sensitizer and affects ovarian androgen synthesis.
Grape seed extract: An antioxidant that promotes normal cell development and guards against oxygen radicals.
Lycopene: Lycopene is the single most potent carotenoid antioxidant.

Additional information

Weight	1 lbs

Supplement Facts
Serving Size: 1 Scoop (2.4g)
Servings per Container: 120 (60 Day Supply)
	Amount per Serving:	DV%
Myo-Inositol	2,000 mg	†
D-chiro-Inositol	50 mg	†
Grapeseed Extract 95%	100 mg	†
Lycopene 10%	15 mg	†
* Percent Daily Values are based on 2,000 calorie diet. † Daily Value not established. Suggested usage: One scoop, twice daily in a non-carbonated flavored beverage

The Scientific Basis:

Polycystic Ovary Syndrome (PCOS) is a set of symptoms including irregular or absent menstrual periods, elevated levels off masculinizing hormones (leading to acne, increases in facial and body hair growth) and infertility (due to lack of ovulation). One of the most common endocrine disorders, it affects up to 15% of women of reproductive age. Serum insulin levels and insulin resistance are higher in PCOS and both elevated androgen and insulin levels play major roles in the genesis of this syndrome. PCOS is, in fact, a multi-organ disorder, with inappropriate communication among the hypothalamus, pituitary, adrenal gland and ovaries, with other organs being affected. The diagnosis of PCOS can only be made after excluding other disorders involving excessive androgens. Although there is no cure for PCOS, initial treatment should include a proper diet, aerobic exercise, and weight loss, where indicated. These measures reduce insulin resistance and may restore normal, ovulatory menstrual cycles. Certain insulin sensitizing drugs, e.g., metformin and thiazoladines, have been used to combat the ovulation dysfunction associated with elevated circulating insulin levels; however, these medications are not without side effects and may be poorly tolerated in some PCOS patients. Another first-order treatment for PCOS is the inositols, part of the B complex of vitamins found in many foods including nuts, grains, beans as well as fresh vegetables and fruits (especially melons and citrus). Several studies have shown that two inositols, myo-inositol (MI) and D-chiro-inositol (DCI), are also insulin-sensitizing agents that can improve several abnormalities in PCOS. MI and DCI are stereoisomers (identical molecular formula but different three - dimensional structures) that seem work best in the treatment of PCOS in a 40:1 ratio. DCI and MI, the form of inositol found in food and synthesized from glucose by the liver and the kidneys, act as “second messengers,” modulating the effects of several hormones, including insulin, follicle stimulating hormone (FSH) and thyroid stimulating hormone (TSH). DCI seems to mediate insulin activities in tissues other than the ovary; however, MI affects the ovary, by facilitating glucose uptake and FSH signaling. With respect to reproduction, MI has actions in egg development and maturation, fertilization and early embryonic development. A number of investigations have demonstrated that DCI and MI are able to reduce the LH/FSH ratio, serum LH and testosterone levels and restore spontaneous, ovulatory menstrual cycles as well as improve associated oily skin, acne, and increases in facial and body hair growth. MI improves sensitivity to injectable recombinant FSH (rFSH), e.g., Gonal-F and Follistim in the ovulation induction and IVF setting, leading to a reduction in the amount of rFSH and the duration of treatment. MI and DCI in a 40:1 ratio have also been shown to improve oocyte quality and pregnancy rates in IVF and reverse the metabolic aberrations of PCOS including lipid profiles, thereby reducing risks of cardiovascular disease. Prolog PCOS Formula is well tolerated with few side effects and its use is to be highly recommended in all PCOS patients. All products are made in the USA with all ingredients of the highest verifiable quality. Disclaimer: None of the above statements have been evaluated by the United States Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure or prevent any disease. Please consult your health care professional before taking any and all supplements, Individual results may vary. Every Prolog Health product exceeds the standards and requirements set forth in the FDA's Code of Federal Regulation (21 CFR, 111) Current Good Manufacturing Practices (CGMP). References:

Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS: Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. 2015 Endocrine Reviews (Review) 36(5): 487–525.
Hanson B, Johnstone E, Dorais J, Silver B, et al: Female infertility, infertility-associated diagnoses, and comorbidities: a review. 2016 J Asst Reprod Genet 34(2) 167-177.
Marine L C, Christophe O S: Potential role and therapeutic interests of myo-inositol in metabolic diseases. 2013 Biochimie, 95, 1811-27.
Chiu T T, Rogers M S, Law E L, et al: Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. 2002 Hum Reprod, 17(6), 1591-6.
Nestler J E, Jakubowicz D J, Baillargeon J P et al: Ovulatory and metabolic effects of D-chiro-inositol in the polycycstic ovary syndrome. 1999 N Engl J Med, 340, 1314-20.
Papaleo E, Unfer V, Baillargeon JP, De Santis L, et al: Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction. 2007 J Gynecol Endocrinol 23(12) 700-703.
Nestler J E, Unfer V: Reflections on inositol(s) for PCOS therapy: steps toward success. 2015 Gynecol Endocrinol, 31(7), 501-5.
Gerli S, Papaleo E, Ferrari A, DiRenzo GC: Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. 2007 Eur Rev Med Pharmacol Sci 11:347-354.
Papaleo E, Unfer V, Baillargeon J P: Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009, 91(5), 1750-4.
Monastra G, Unfer V, Harrath AH, Bizzarri M: Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. 2017 33(1) 1-9.
Minozzi M, Nordio M, Pajalich R: The combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci 2013 17, 537-40.
Bahmani F, Karamali M, Shakeri H: The effects of folate supplementation on inflammatory factors and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome; a randomized, double-blind, placebo controlled clinical trial. 2014 Clin Endocrinol 81(4) 582-587.
Kamenov Z. Gateva A: Inositols in PCOS. Molecules 2020, 25(23), 5566; https://doi.org/10.3390/molecules25235566
Lervolino M, Lepore E, Forte G, Lagana AS, et al: Natural molecules in the management of polycystic ovary syndrome (PCOS): An analytical review. Nutrients 2021. 13(5). 1677; https://doi.org/10.33901nu13051677
Davinelli S, Nicolosi D, Di Cesare C, Scapagnini G, Di Marco R: Targeting metabolic consequences of insulin resistance in polycystic ovary syndrome by D-chiro-inositol and emerging nutraceuticals: a focused review. Clin Med. 2020, 9(4), 987; https://doi.org/10.3390/jcm9040987

Description

Additional information

The Scientific Basis:

Shop Our Products

About

My Account

Products

Helpful Info